69 related articles for article (PubMed ID: 19893579)
1. No influence of FAT polymorphisms in response to aripiprazole.
Pae CU; Chiesa A; Mandelli L; De Ronchi D; Serretti A
J Hum Genet; 2010 Jan; 55(1):32-6. PubMed ID: 19893579
[TBL] [Abstract][Full Text] [Related]
2. No influence of DTNBP1 polymorphisms on the response to aripiprazole.
Pae CU; Chiesa A; Mandelli L; Serretti A
Neuropsychobiology; 2010; 62(4):245-9. PubMed ID: 20829635
[TBL] [Abstract][Full Text] [Related]
3. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
Kwon JS; Kim E; Kang DH; Choi JS; Yu KS; Jang IJ; Shin SG;
Eur Neuropsychopharmacol; 2008 Dec; 18(12):897-907. PubMed ID: 18786813
[TBL] [Abstract][Full Text] [Related]
4. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
5. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
[TBL] [Abstract][Full Text] [Related]
6. Influence of TAAR6 polymorphisms on response to aripiprazole.
Serretti A; Pae CU; Chiesa A; Mandelli L; De Ronchi D
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(5):822-6. PubMed ID: 19345712
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
[TBL] [Abstract][Full Text] [Related]
8. Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole.
Pae CU; Chiesa A; Serretti A
Psychiatry Res; 2010 Jul; 178(2):430-2. PubMed ID: 20471098
[TBL] [Abstract][Full Text] [Related]
9. Trial of aripiprazole in the treatment of first-episode schizophrenia.
Lee HY; Ham BJ; Kang RH; Paik JW; Hahn SW; Lee MS; Lee MS
Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
Mitsonis CI; Dimopoulos NP; Mitropoulos PA; Kararizou EG; Katsa AN; Tsakiris FE; Katsanou MN
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):373-7. PubMed ID: 17092620
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
[TBL] [Abstract][Full Text] [Related]
13. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
Shen YC; Chen SF; Chen CH; Lin CC; Chen SJ; Chen YJ; Luu SU
J Psychiatr Res; 2009 Mar; 43(6):600-6. PubMed ID: 18926547
[TBL] [Abstract][Full Text] [Related]
14. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.
Chen SF; Shen YC; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):470-4. PubMed ID: 19302829
[TBL] [Abstract][Full Text] [Related]
15. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study.
Christensen AF; Poulsen J; Nielsen CT; Bork B; Christensen A; Christensen M
Acta Psychiatr Scand; 2006 Feb; 113(2):148-53. PubMed ID: 16423167
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee JH; Lee YH; Yang SJ; Yoon JS
Clin Neuropharmacol; 2009; 32(5):243-9. PubMed ID: 19620849
[TBL] [Abstract][Full Text] [Related]
18. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders.
Yoo HK; Choi SH; Park S; Wang HR; Hong JP; Kim CY
J Clin Psychiatry; 2007 Jul; 68(7):1088-93. PubMed ID: 17685747
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole may be free from tachyphylaxis: preliminary findings.
Goto S; Terao T; Tomita M; Uchimura N
Psychiatry Clin Neurosci; 2012 Mar; 66(2):160-2. PubMed ID: 22300307
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A;
J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
